Jerry Schreibstein, MD
Otolaryngology · Springfield, MANPI 1265499370
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,000 of the $2,373 with a category attached, or 84.3%. Optinose US, Inc. accounts for 84.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $2,000 and has fallen 98.4% since, to $33 in 2025.
Across 13 payments — averaging $182.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$2K
- Intersect ENT, Inc.$205
- Sanofi$81
- Smith+Nephew$45
- Sanofi-aventis U.S. LLC$41
What the payments were for
- Consulting fees$2,00084%
- Food & beverage$37316%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 1 | $2,000 |
| Intersect ENT, Inc. | 4 | $205 |
| Sanofi | 5 | $81 |
| Smith+Nephew | 1 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xhance$2,000
How this compares
$2,373 in reported general payments places this provider in the 75th percentile of 298 otolaryngology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 19 | $81,725 |
| Dupixent SyringeDupilumab | 22 | $78,058 |
| Epinephrine | 30 | $7,543 |
| Budesonide | 52 | $6,785 |
| Ipratropium Bromide | 195 | $6,654 |
| Azelastine Hcl | 135 | $4,011 |
| Fluticasone Propionate | 237 | $3,705 |
| Montelukast Sodium | 63 | $966 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 19 | $832 |
| Doxycycline Hyclate | 55 | $496 |
| Clotrimazole | 15 | $370 |
| Fluocinolone Acetonide Oil | 14 | $355 |
| Mupirocin | 14 | $103 |
| Prednisone | 19 | $79 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Springfield
- Theodore MasonSpringfield$4K
- Ayesha KhalidConcord$511K
- Dennis PoeBoston$264K
- Peter WeberBoston$157K
- Kevin EmerickBoston$89K
- Benjamin BleierBoston$77K
- Gregory RandolphBoston$56K
- Daniel LeeBoston$52K
- Pratik PradhanBrockton$51K
- Marika RussellBoston$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.